article thumbnail

Healthy Data Management: How IT Assists Healthcare Institutions

Healthcare IT Today

Confidentiality Laws and regulations govern the confidentiality of medical data. Medical records remain a desirable target for cybercriminals as they can be used for fraud or ransom demands. About Natalie Tkachenko Natalie is a HIPAA-certified expert with high-grade knowledge in the healthcare and pharmaceutical industries.

article thumbnail

Healthy Data Management: How IT Assists Healthcare Institutions

HIT Consultant

Confidentiality Laws and regulations govern the confidentiality of medical data. Medical records remain a desirable target for cybercriminals as they can be used for fraud or ransom demands. State documents define rules for collecting, storing, processing, and transmitting medical information.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How to Tackle Pharma’s 3 Biggest Compliance Risks Head-On with Verisys

Verisys

The onus of ensuring these CROs have proper controls in place often falls on the shoulders of the pharmaceutical company and can be challenging to monitor. Medication Samples Supplying medication samples to prescriber’s offices is common in the pharmaceutical industry, especially with launch brands.

article thumbnail

Health Provider News

Hall Render

health care fraud scheme SA cancer research company entering Dallas market as it eyes more U.S., health care fraud scheme SA cancer research company entering Dallas market as it eyes more U.S., European expansion North Texas podiatrist and patient recruiter convicted in $8.5M

article thumbnail

Shameless Plug: Reed Smith’s Virtual Life Sciences Litigation CLE Day (Nov. 16)

Drug & Device Law

Plaintiffs’ counsel seem to be increasingly setting their sights on the OTC segment of the pharmaceutical industry, where the Learned Intermediary Doctrine does not serve as a barrier, where vast use of OTC products expands the range of potential plaintiffs, and where litigation can target well-known prescription drug parent companies.

FDA 59